Evidence map›Paper›PMID 33542691›Full record

ArticleFrontiers in pharmacology2020

Emodin Inhibits the Proliferation of MCF-7 Human Breast Cancer Cells Through Activation of Aryl Hydrocarbon Receptor (AhR).

Ning Zhang, Jiawen Wang, Aimin Sheng, Shuo Huang, Yanyan Tang, Shitang Ma, Ge Hong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Function and Application of Flavonoids in the Breast Cancer.International journal of molecular sciences · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ning ZhangLife and Health College, Anhui Science and Technology University, Fengyang, China.
Jiawen WangSchool of Pharmacy, East China University of Science and Technology, Shanghai, China.
Aimin ShengSchool of Chemical Engineering, Anhui University of Science and Technology, Huainan, China.
Shuo HuangClinical College of Orthopedics, Tianjin Medical University, Tianjin Hospital, Tianjin, China.
Yanyan TangClinical College of Orthopedics, Tianjin Medical University, Tianjin Hospital, Tianjin, China.
Shitang MaLife and Health College, Anhui Science and Technology University, Fengyang, China.
Ge HongTianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
Anhui University of Science and Technology · CNTianjin Medical University · CNAnhui Science and Technology University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNEast China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products have proved to be a promising source for the development of potential anticancer drugs. Emodin, a natural compound from

Indexed as

AhRbreast cancerCYP1A1emodinMCF-7network pharmacology

Identifiers

PMID33542691
PMCPMC7850984
OpenAlexW3121155202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.